BAMF
ADMA icon

BI Asset Management Fondsmaeglerselskab’s ADMA Biologics ADMA Stock Holding History

BI Asset Management Fondsmaeglerselskab’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-8,606
Closed -$171K – 744
2025
Q1 		$171K Sell
8,606
-101,457
-92% -$1.75M ﹤0.01% 636
2024
Q4 		$1.89M Buy
+110,063
New +$2.07M 0.02% 370

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab's ADMA Position: Q2 2025 in Review

BI Asset Management Fondsmaeglerselskab sold out of ADMA Biologics (ADMA) in Q2 2025, closing a stake of 8,606 shares — an estimated $171K sold.

BI Asset Management Fondsmaeglerselskab first reported a position in ADMA in Q4 2024 and held it in 2 quarters. The position peaked at $1.89M in Q4 2024. 368 funds tracked by Wall St. Rank hold ADMA as of Q2 2025.

  • BI Asset Management Fondsmaeglerselskab reported no remaining ADMA Biologics position as of Q2 2025 after selling out during the quarter.
  • BI Asset Management Fondsmaeglerselskab sold 8,606 ADMA Biologics shares in Q2 2025, an estimated $171K.
  • BI Asset Management Fondsmaeglerselskab first reported a position in ADMA Biologics in Q4 2024 and held it in 2 quarters.
  • BI Asset Management Fondsmaeglerselskab's ADMA Biologics position peaked at $1.89M in Q4 2024.
  • 368 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2025.

Based on BI Asset Management Fondsmaeglerselskab's 13F filing for Q2 2025, filed 14 Aug 2025.